First human test of new Vision-Saving eye injection shows promise
NCT ID NCT05643118
Summary
This was a first-in-human study to check the safety of a new drug, OLX10212, for wet age-related macular degeneration (AMD). It involved 21 patients who received injections of the drug into their eye. The main goal was to see if the treatment was safe and tolerable, while also looking for early signs that it might help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Retina Consultants
Santa Maria, California, 93434, United States
-
Ophthalmic Consultants of the Capital Region
Troy, New York, 12180, United States
-
Texas Retina Consultants
Bellaire, Texas, 77401, United States
-
The Retina Institute
St Louis, Missouri, 63128, United States
-
University Retina
Oak Forest, Illinois, 60452, United States
Conditions
Explore the condition pages connected to this study.